10.6084/m9.figshare.c.3783296_D1.v1
Akinori Yamaguchi
Akinori
Yamaguchi
Makoto Harada
Makoto
Harada
Yosuke Yamada
Yosuke
Yamada
Koji Hashimoto
Koji
Hashimoto
Yuji Kamijo
Yuji
Kamijo
Additional file 1: Table S1. of Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study
Springer Nature
2017
Chronic kidney disease
Febuxostat
Hyperuremia
Uric acid
Vascular risk factors
2017-05-18 05:00:00
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Table_S1_of_Identification_of_chronic_kidney_disease_patient_characteristics_influencing_the_renoprotective_effects_of_febuxostat_therapy_a_retrospective_follow-up_study/5023652
Adverse events. There were 15 cases wherein febuxostat treatment was discontinued owing to various adverse events. In most patients, the adverse events developed during the initial dosing of febuxostat at 10Â mg/day. (DOCX 18Â kb)